Overview
Sage Therapeutics is a biopharmaceutical company pioneering GABA and NMDA receptor-targeted medicines for brain health disorders, with Zurzuvae (zuranolone) being the first once-daily oral pill FDA-approved for postpartum depression. They continue to advance a pipeline targeting major depressive disorder, epilepsy, and essential tremor.
More in Neuropharmaceuticals
Latest industry news
BlueWind Medical's Revi Extend Wins FDA Clearance, Extending Implant Life to 15 Years
2026-08-06 · Product
Neurofeedback Systems Market Eyes $2.95 Billion Valuation by 2035 as Clinical and Consumer Demand Converge
2026-08-05 · Industry
Smaller Neuromodulation Devices Are Reshaping the Competitive Landscape for TMS Providers
2026-08-04 · Industry
NIH-Backed Brain-Computer Device Restores Speech in Paralyzed Patient
2026-08-03 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
Cambridge, MA, USA
Funding
NASDAQ: SAGE
Website
sagerx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →